STIM — Neuronetics Income Statement
0.000.00%
- $177.88m
- $226.81m
- $74.89m
Annual income statement for Neuronetics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 49.2 | 55.3 | 65.2 | 71.3 | 74.9 |
| Cost of Revenue | |||||
| Gross Profit | 37.7 | 43.7 | 49.7 | 51.7 | 54.2 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 72.5 | 82.9 | 100 | 102 | 114 |
| Operating Profit | -23.2 | -27.6 | -35.1 | -30.6 | -39 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -27.5 | -31.2 | -37.2 | -30.2 | -43.7 |
| Net Income After Taxes | -27.5 | -31.2 | -37.2 | -30.2 | -43.7 |
| Minority Interest | |||||
| Net Income Before Extraordinary Items | |||||
| Net Income | -27.5 | -31.2 | -37.2 | -30.2 | -43.7 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -27.5 | -31.2 | -37.2 | -30.2 | -43.7 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -1.41 | -1.17 | -1.36 | -1.05 | -1.11 |